Date:5/7/2012

that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com

'/>"/>

SOURCE ThermoGenesis Corp. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China
2. ThermoGenesis Announces Webcast of Presentation at Roth Capital Conference
3. ThermoGenesis Reports Second Quarter Fiscal 2012 Results
4. ThermoGenesis Provides Update on Res-Q® Clinical Evaluations at Leading Stem Cell Therapy Conference
5. Canadas First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System
6. Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications
7. ThermoGenesis Announces Webcast of Presentation at OneMedForum Conference
8. ThermoGenesis Corp. to Announce First Quarter Fiscal 2012 Results on November 10, 2011
9. ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent
10. ThermoGenesis Presentation at Rodman & Renshaw Conference
11. ThermoGenesis Names Former Applied Imaging CEO Robin Stracey to Board of Directors, Replacing Dr. Mahendra Rao